MedPath

Analysis of Clinical Trials for Recurrent Spontaneous Abortion Reveals Research Gaps

• A review of 138 clinical trials on ClinicalTrials.gov highlights the landscape of research into recurrent spontaneous abortion (RSA). • The majority of trials focus on intervention strategies, particularly drug interventions like anticoagulants, for unexplained RSA (URSA). • Asia leads in the number of RSA clinical trials, followed by Europe and Africa, indicating a global interest in addressing this reproductive challenge. • The study suggests current research efforts may be inadequate, pointing to the need for more diverse and effective prevention and treatment strategies.

A systematic review of clinical trials registered on ClinicalTrials.gov reveals significant gaps in research and intervention strategies for recurrent spontaneous abortion (RSA). The analysis, encompassing 138 trials, highlights a concentration on drug interventions, particularly anticoagulants, for unexplained RSA (URSA), suggesting a need for more diverse approaches.

Trial Characteristics

The study, published in Frontiers in Endocrinology, examined trials registered up to March 2, 2024. Of the 138 trials identified, 72 (52.17%) were classified as intervention trials, while 66 (47.83%) were observational. A significant portion (48.55%) of the studies enrolled 100 or fewer participants, and the majority focused exclusively on female participants. Geographically, Asia hosted the highest number of trials (46, 33.33%), followed by Europe (36, 26.09%), Africa (29, 21.01%), and America (13, 9.42%).

Focus on Unexplained RSA and Drug Interventions

The analysis indicated that 61 trials (44.20%) specifically targeted individuals with URSA. Among intervention types, drug interventions were predominant (49, 62.82%), with a notable increase in behavioral intervention trials also observed. The emphasis on drug interventions, particularly anticoagulants, suggests a prevailing hypothesis regarding the role of coagulation disorders in RSA, but also highlights a potential lack of exploration into other potential etiologies and therapeutic strategies.

Implications for Future Research

The authors suggest that current research efforts in RSA are insufficient for advancing prevention and treatment strategies. The concentration on URSA and drug interventions, particularly anticoagulants, may overlook other contributing factors and potential therapeutic avenues. The review underscores the need for more comprehensive and diversified research approaches to address the complex challenges of RSA. Further research should explore a broader range of interventions and consider the diverse underlying causes of RSA to improve outcomes for affected women.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Global Review Highlights Clinical Trial Landscape for Relapsed Multiple Myeloma

A comprehensive review of global clinical trials for relapsed multiple myeloma (R/R MM) reveals key trends in trial locations, phases, and sponsor types.
The analysis identifies prominent drugs under investigation and highlights recent clinical trial news, including updates from ASH 2024 and other major meetings.

Radiopharmaceutical Development Shows Promise with Targeted Alpha Therapies on the Rise

Analysis of 361 radiopharmaceutical clinical trials reveals that only 52.9% are active, with most in early phases.
Beta-emitting radionuclides are currently predominant, but alpha radiation drug development is gradually emerging in popularity.

AstraZeneca Expands Clinical Trial Footprint in South Africa, Bolstering Global Research Efforts

AstraZeneca has significantly increased its clinical trial activity in South Africa, marking the country as a key hub for global medical research and innovation.
The company's clinical trials in South Africa have grown by 94% since 2021, encompassing critical areas such as cardiovascular, respiratory, and oncology diseases.

Adoptive Cell Therapy Clinical Trials Show Promising Growth and Regional Shifts

Adoptive cell therapy clinical trials are increasing, with 42% currently ongoing, suggesting a potential influx of novel therapies in the near future.
CAR-T treatments dominate T cell immunotherapy trials, accounting for 83% of them, and represent 55% of all adoptive cell therapy trials.

Adaptive Clinical Trials: Study Highlights Inconsistencies in Sample Size Reporting

A review of 265 adaptive clinical trials reveals that less than half explicitly report the operating characteristics of the adaptive design, impacting result interpretation.
While most trials (86.4%) clearly describe interim decision rules, replicability is a concern as 61.3% fail to specify if futility stopping rules are binding or non-binding.

Aspirin and Heparin Combination Significantly Improves Live Birth Rates in Women with Recurrent Pregnancy Loss

A Kobe University-led study reveals that low-dose aspirin or heparin treatment significantly increases live birth rates in women with recurrent pregnancy loss who test positive for specific self-targeting antibodies.
The research indicates that treatment with aspirin or heparin led to an 87% live birth rate, compared to 50% in untreated women, showcasing a substantial improvement in pregnancy outcomes.

HPV Clinical Trial Analysis Reveals Gaps in Prospective Registration and Data Completion

A cross-sectional analysis of 1632 HPV clinical trials registered between 1999 and 2023 reveals inconsistencies in trial registration practices.
The study highlights a significant number of trials registered retrospectively, failing to adhere to prospective registration guidelines.

Systematic Review of Phase II and III Clinical Trials for Relapsing Multiple Sclerosis

A comprehensive systematic review of phase II and III clinical trials for relapsing multiple sclerosis (RMS) has been conducted, focusing on trial designs and primary endpoints. The review, which analyzed 60 trials from three major trial registration systems, highlights the dominance of randomized controlled parallel-arms trials and discusses the most common primary endpoints across different trial phases and patient groups. The findings suggest a need for revisions in regulatory guidelines and expert recommendations to better align with current clinical trial practices.

COVID-19 Trial Reporting Lags, Hampering Research Efficiency

A systematic review reveals that the majority of registered COVID-19 trials have not reported results, hindering research progress.
Most published trials focus on hospitalized patients, leaving gaps in outpatient and preventative treatment evidence.

Global COVID-19 Clinical Trial Landscape: Unprecedented Research Response Marked by Coordination Challenges

A comprehensive analysis of 683 COVID-19 clinical trials revealed an unprecedented surge in research activity during the pandemic's first 100 days.
The review highlights concerns over trial coordination, with many small trials potentially duplicating efforts and straining research resources.

Reference News

[1]
The Landscape of Recurrent Spontaneous Abortion Registered on Clinical Trials.gov
frontiersin.org · Dec 3, 2024

A systematic review of recurrent spontaneous abortion (RSA) clinical trials on ClinicalTrials.gov identified 138 trials,...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy